Latest news with #GuillaumeDaniellot
Yahoo
01-05-2025
- Business
- Yahoo
Straumann Holding AG (SAUHF) Q1 2025 Earnings Call Highlights: Strong Organic Growth Amid ...
Revenue: CHF681 million, reflecting an organic growth of 11%. Core EBIT Margin: Expected improvement of 30 to 60 basis points at constant 2024 currency rates. Dividend: Increased by 12% compared to the previous year. Regional Performance: Strong double-digit growth in EMEA, APAC, and Latin America; positive growth in North America despite soft demand. Product Segments: Significant growth across implantology, orthodontics, and digital solutions. Market Share: Approximately 12.5% in the global market, with 35% in implantology. Manufacturing Expansion: 19 production facilities worldwide, with new sites in Shanghai and Curitiba under development. Warning! GuruFocus has detected 6 Warning Sign with BCS. Release Date: April 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Straumann Holding AG (SAUHF) reported strong organic revenue growth of 11% in Q1 2025, reaching CHF681 million. The company saw significant performance in the EMEA and APAC regions, with double-digit growth in emerging markets like Thailand, India, and Malaysia. Straumann's collaboration with SprintRay and the launch of the Straumann Access platform mark significant advancements in digital dentistry. The company's multi-brand and multi-price strategy has been effective in gaining market share across different customer segments. Straumann is investing in expanding its manufacturing footprint, with new facilities in China and Brazil to support growth and supply chain resilience. The macroeconomic environment remains uncertain, impacting consumer sentiment and leading to soft demand in North America. Foreign exchange headwinds could pose challenges in the coming quarters due to the strengthening of the CHF. The orthodontics business in North America remains soft, affecting overall regional performance. Tariffs and geopolitical complexities could impact financials, although measures are in place to mitigate these effects. The company faces competitive pressures in the US market, with price competition remaining high. Q: Can you elaborate on the guidance for 2025, considering the strong start to the year and the macroeconomic uncertainties? A: Guillaume Daniellot, CEO: We are pleased with our first quarter performance. Despite the uncertainties, we believe that achieving high-single digit growth is a significant objective. The macroeconomic environment remains unpredictable, so we are cautious. If conditions remain favorable, we may revise our guidance later in the year. Q: Which new products do you expect to drive growth in the next 12 to 24 months? A: Guillaume Daniellot, CEO: The iEXCEL implant system is expected to grow our market share in the premium segment. Our digital solutions, particularly the scanner portfolio, are gaining traction in markets like Brazil and China. Additionally, our partnership with SprintRay for chairside 3D printing could significantly impact single-visit restorations. Q: Are you seeing any softness in the US or Europe due to macroeconomic headwinds? A: Guillaume Daniellot, CEO: In North America, we observed volatility rather than a consistent decline. The market is reacting to macroeconomic news, but we ended the quarter stronger than expected. We anticipate a more stable environment in the coming months. Q: What are the expected foreign exchange and tariff impacts for the rest of the year? A: Xu Yang, CFO: We saw minimal foreign exchange impact in Q1, but future headwinds could be around 100 basis points on the top line. Tariffs are embedded in our guidance, and our global network helps mitigate their impact, though we are not immune. Q: How is the US market expected to perform in 2025 compared to 2024? A: Guillaume Daniellot, CEO: Despite unpredictability, we expect 2025 to outperform 2024. We have strong fundamentals, including innovation and market share gains, which should support growth even in a challenging macro environment. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Reuters
19-02-2025
- Business
- Reuters
Dental implant maker Straumann expects China demand to lift 2025 growth
Feb 19 (Reuters) - Swiss dental implant maker Straumann Holding (STMN.S), opens new tab expects rising demand from China to help boost sales growth this year, it said on Wednesday after reporting 2024 revenues that matched market estimates. Straumann, which specialises in tooth replacement and orthodontic solutions, said Asia-Pacific sales grew 33% in 2024, helped by China's initiative to reduce the price of medicines as part of a new procurement policy, and increased market share. Under China's new volume-based procurement model, implant prices for end customers have fallen sharply, boosting demand in the country. "The whole 2025, we believe, will still be beneficial for the patient flow remaining dynamic because what has been unlocked as a patient pool is really massive," CEO Guillaume Daniellot told Reuters. He said the company was in a strong position to grow in China this year. Asia-Pacific accounts for more than a fifth of the company's sales. The group reported 13.7% organic revenue growth to 2.5 billion francs ($2.77 billion) last year, roughly in line with analysts' average forecast of 2.49 billion francs in a poll compiled by Vara Research. It's shares were lower in early trade by later recovered and were up 2.7% at 1133 GMT. Straumann expects overall sales growth in 2025 to be in the high single-digit percentage range, with the margin on earnings before interest and taxes (EBIT) for the year seen improving by 30 to 60 basis points at constant currency rates. Its core EBIT margin came in at 26% in 2024, slightly below the consensus expectation of 26.5%. Full year core net profit rose to 502 million Swiss francs ($556 million) from 482 million francs the previous year. But Straumann's North America business, which makes up 28% of its revenue, grew just 3.6% organically in 2024 although Daniellot pointed to signs of improvement. "We are seeing some light increase in patient traffic since the end of the election period in the U.S. ... and then we hope to have sequential improvement quarter by quarter," he said. ($1 = 0.9033 Swiss francs)
